Register
Dacomitinib approved for first-line use in EGFRm NSCLC |
Journal Updates
eMediNexus Coverage from: 
Dacomitinib approved for first-line use in EGFRm NSCLC
eMediNexus,  29 September 2018
remove_red_eye 671 Views
#Hematology #Oncology #Pharmacist #Pulmonary Medicine

0 Read Comments                

Dacomitinib (Vizimpro, Pfizer) has been approved by the US FDA for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC). with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now